You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 29, 2024

~ Buy the AURYXIA (ferric citrate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR AURYXIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Auryxia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01554982 ↗ A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed Keryx Biopharmaceuticals Phase 3 2012-08-01 A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial.
NCT02492620 ↗ Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D Completed Keryx Biopharmaceuticals Phase 3 2015-03-01 It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.
NCT02492620 ↗ Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D Completed Denver Nephrologists, P.C. Phase 3 2015-03-01 It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.
NCT02661295 ↗ A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status Keryx Biopharmaceuticals Phase 4 2015-07-01 The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population. This is due in part to high levels of inflammation and vascular calcification found in these patients. Phosphate binders, particularly non-calcium based phosphate binders, may decrease cardiovascular risk by decreasing inflammation and vascular calcification. Ferric citrate a non-calcium based phosphate binder with approximately 210 mg of ferric iron has recently been approved for patients on hemodialysis. The effect of this phosphate binder on inflammation and lipid levels is unknown but investigators hypothesize that ferric citrate has the potential to improve inflammation and lipid levels in patients on hemodialysis by decreasing intravenous iron requirements and by improving lipid metabolism.
NCT02661295 ↗ A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status Winthrop University Hospital Phase 4 2015-07-01 The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population. This is due in part to high levels of inflammation and vascular calcification found in these patients. Phosphate binders, particularly non-calcium based phosphate binders, may decrease cardiovascular risk by decreasing inflammation and vascular calcification. Ferric citrate a non-calcium based phosphate binder with approximately 210 mg of ferric iron has recently been approved for patients on hemodialysis. The effect of this phosphate binder on inflammation and lipid levels is unknown but investigators hypothesize that ferric citrate has the potential to improve inflammation and lipid levels in patients on hemodialysis by decreasing intravenous iron requirements and by improving lipid metabolism.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Auryxia

Condition Name

Condition Name for Auryxia
Intervention Trials
Hyperphosphatemia 6
End Stage Renal Disease 3
Renal Insufficiency 2
Anemia, Iron Deficiency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Auryxia
Intervention Trials
Hyperphosphatemia 6
Renal Insufficiency, Chronic 5
Anemia, Iron-Deficiency 4
Renal Insufficiency 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Auryxia

Trials by Country

Trials by Country for Auryxia
Location Trials
United States 30
Puerto Rico 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Auryxia
Location Trials
California 3
Texas 3
Colorado 2
Indiana 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Auryxia

Clinical Trial Phase

Clinical Trial Phase for Auryxia
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Auryxia
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 1
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Auryxia

Sponsor Name

Sponsor Name for Auryxia
Sponsor Trials
Keryx Biopharmaceuticals 5
Akebia Therapeutics 2
USRC Kidney Research 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Auryxia
Sponsor Trials
Other 8
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.